Every 10-Q that HEPION PHARMS INC (HEPA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HEPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HEPA filings page.
Hepion Pharmaceuticals, Inc. reports no revenue for the three and six months ended June 30, 2026 as it transitions from drug development to liver disease diagnostics. The company recorded a net loss of $1.25 million for the quarter and $2.06 million for the first half of 2026, a substantial improvement from a $7.15 million loss in the prior-year six‑month period, driven by lower operating expenses and a much smaller loss from warrant revaluation.
At June 30, 2026, cash was $1.63 million, total assets were $1.93 million, liabilities $0.65 million and stockholders’ equity $1.28 million, with working capital of $1.4 million. Management states there is substantial doubt about the ability to continue as a going concern without additional capital. After quarter‑end, Hepion raised $3.1 million in a July 2026 private placement of 61.1 million common shares and warrants and had 90,219,317 common shares outstanding as of August 10, 2026.
The company licensed liver disease diagnostic assets from Cirna Diagnostics for a $70,000 upfront payment, with potential milestones and low single‑digit royalties, and terminated a prior New Day license, recovering 346,020 shares. Material weaknesses in internal control over financial reporting are disclosed, including insufficient personnel and weak controls over complex transactions and income tax reporting, with remediation plans dependent on raising further capital.
Hepion Pharmaceuticals reported a first-quarter 2026 net loss of $810,791, a sharp improvement from $6,105,887 a year earlier, driven mainly by lower general and administrative costs and a much smaller warrant-related fair value loss.
The company generated no revenue and remains pre-commercial. Operating expenses were $798,509, including $70,000 of research and development largely tied to a new Cirna Diagnostics liver-disease diagnostic license, which was expensed as in‑process R&D.
Cash was $2,602,580 at March 31, 2026, aided by a one‑time $1,000,000 refund from a prepaid insurance policy. Hepion subsequently raised $700,000 in an April 21 private placement of 17,500,000 common shares at $0.04 per share, with $250,000 recorded as a subscription liability at quarter‑end.
Management reports an accumulated deficit of $246,908,447 and concludes there is “substantial doubt” about the company’s ability to continue as a going concern without additional capital. The filing also discloses material weaknesses in internal controls and notes the March 16, 2026 resignation of the CEO, followed by a separation agreement providing cash and COBRA benefits.
Hepion Pharmaceuticals (HEPA) filed its Q3 2025 10‑Q, showing a continued business pivot from liver drug development to medical diagnostics. The company reported a Q3 net loss of $472,506 and a nine‑month net loss of $7,620,965. Operating expenses fell sharply as research and development dropped to zero for the quarter, while general and administrative expense was $527,902.
Cash was $2,321,078 at September 30, 2025, with total liabilities of $415,808 and stockholders’ equity of $3,324,432. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. Shares outstanding were 11,620,317 as of November 12, 2025.
Hepion in‑licensed diagnostic tests from New Day Diagnostics on May 9, 2025, paying $525,000 cash and $270,629 in stock, with up to $17.15 million in potential milestones; it recorded a $402,746 impairment. On May 26, 2025, it sold all rencofilstat assets to Panetta Partners for a nominal amount, with CVRs tied to future FDA approval and sales milestones. Earlier, the company raised approximately $9.0 million (January 23, 2025), repaid $2.9 million notes, effected a 1‑for‑50 reverse split, and transitioned trading to OTCQB after Nasdaq delisting.